EMElena V. Mironova

Elena V. Mironova

*This is an algorithmically generated author record based on publicly available information.

Elena V. Mironova has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated management of a polymorbid patient with hypertension and coronary artery disease: A case report and literature review

    by O. D. Ostroumova, S. S. Telkova, A. I. Kochetkov, A. A. Tyazhelnikov, E. V. Mironova, N. M. Doldo, О. Д. Остроумова, С. С. Телкова, A. И. Кочетков, А. А. Тяжельников, et al.

    Arterial hypertension (AH) remains a leading risk factor for cardiovascular complications and cognitive impairment. Effective control of blood pressure (BP) significantly reduces the risk of stroke and coronary artery disease (CAD). However, in real-world clinical practice, achieving target BP levels is often complicated by comorbidities, poor treatment adherence, and neglect of the circadian BP profile, particularly morning BP surges, which are an independent predictor of cardiovascular events. Among antihypertensive drugs, angiotensin II receptor blockers (ARBs) hold a special place due to their proven cerebroprotective effects. Candesartan, one of the most extensively studied representatives of this class, not only effectively lowers BP but also slows the progression of cognitive impairment and significantly reduces the risk of stroke. The presented clinical case demonstrates the potential for treatment optimization in a patient with long-term uncontrolled AH, CAD, obesity, and established cognitive impairment. Given the presence of morning BP surges and cognitive dysfunction, the patient was prescribed candesartan 16 mg/day in combination with bisoprolol, indapamide, and atorvastatin. For secondary prevention of thrombotic complications, acetylsalicylic acid (ASA) combined with magnesium hydroxide was chosen, which preserves the high bioavailability of the immediate-release ASA formulation while simultaneously providing gastric mucosal protection. After 9 months of therapy, target BP levels were achieved, morning BP surges were eliminated, and improvements in cognitive function and regression of left ventricular hypertrophy were observed. Thus, candesartan, due to its cerebroprotective properties and ultra-long duration of action, is the drug of choice in comorbid patients with AH and cognitive impairment. The combination of ASA with magnesium hydroxide provides an optimal balance of antiplatelet efficacy and gastroprotection.

  • Open Access

    Antithrombotic therapy in coronary artery disease: strategy choice based on comorbidity. A review

    by Olga D. Ostroumova, Aleksey I. Kochetkov, Anna V. Dubinina, Svetlana S. Telkova, Natalia E. Gavrilova, Nicolai M. Doldo, Elena V. Mironova

    Coronary artery disease (CAD) remains a leading cause of mortality, and its frequent coexistence with atrial fibrillation (AF) significantly worsens prognosis, presenting physicians with a complex choice between stroke prevention, protection from coronary events, and minimization of bleeding risk. Even in patients with stable CAD, a high residual risk of thrombotic complications persists, driven by ongoing activation of the coagulation cascade, which traditional antiplatelet monotherapy cannot fully control. The strategy of dual pathway inhibition of thrombus formation has improved treatment outcomes: adding rivaroxaban at a "vascular" dose of 2.5 mg twice daily to acetylsalicylic acid provides a significant reduction in the risk of cardiovascular death and ischemic events with an acceptable safety profile. This approach is justified in patients at high ischemic risk, particularly those with a history of myocardial infarction or multivessel CAD. In the presence of AF, the principles of antithrombotic protection fundamentally change, mandating the inclusion of full-dose anticoagulation. The key strategy to address this challenge is treatment de-escalation: from the shortest possible courses of triple therapy (anticoagulant plus two antiplatelet agents) in the acute phase after percutaneous coronary intervention to dual therapy (anticoagulant plus clopidogrel) during the first year of follow-up. In the long term, stable patients benefit from a transition to anticoagulant monotherapy, which is non-inferior to combination therapy in preventing thrombotic events and significantly superior in terms of safety, as confirmed by large clinical trials and meta-analyses. Thus, rivaroxaban possesses the most comprehensive evidence base among direct oral anticoagulants, covering the entire spectrum of clinical scenarios, from secondary prevention in isolated CAD to the management of patients with concomitant AF. This enables a truly individualized approach, carefully balancing ischemic and bleeding risks in real-world clinical practice.

  • Possibilities of using meldonium as part of complex therapy in patients with ischemic heart disease and chronic heart failure combined with obesity

    by S.V. Litvinova, O.D. Ostroumova, A.I. Kochetkov, E.V. Mironova, I.I. Sinitsyna

    Relevance. Cardiovascular diseases, including coronary heart disease (CHD), remain the leading causes of death worldwide. At the same time, concomitant obesity further increases the risk of adverse cardiovascular events (CVE) and complicates the management of these patients. One of the strategies aimed at increasing the effectiveness of CHD treatment is the use of metabolic therapy to ensure cardiocytoprotection. Aim. To study the effect of the drug Mildronate on the quality of life of patients with coronary heart disease and chronic heart failure (CHF) suffering from obesity. Material and methods. The multicenter, controlled, non-interventional study INDIKOR (Insulin resistance and diabetes mellitus as cardiovascular risk factors: metabolic correctors in combination therapy for coronary heart disease and/or chronic heart failure associated with metabolic syndrome or type 2 diabetes (T2D)) included 2084 patients, median age 62 (55;67) years, with a combination of two (or more) diagnoses (E66/E11+I20/I25/I50): E66 «Obesity»; E11 «Type 2 diabetes mellitus»; I20 «Angina pectoris»; I25 «Chronic ischemic heart disease»; I50 «Heart failure». The present subanalysis for obesity included 1295 patients with a diagnosis of E66 «Obesity». The patients included in the study were divided into 2 groups depending on from taking Mildronate: group 1 — basic therapy for the treatment of concomitant diseases (n=258), group 2 — basic therapy+Mildronate 1000 mg/day (n=1037). The duration of the observation period was 42±2 days. Results: when analyzing the results of the Seattle Angina Quality of Life Questionnaire, patients receiving Mildronate compared with the control group had a statistically significantly higher average total score on the following scales: attack frequency (78.1 [60; 100] versus 64 [40; 80] points, respectively, p<0.001), attack stability (91.8 [75; 100] versus 66.1 [50; 75] points, respectively, p<0.001), limitation of physical activity (53.6 [42.2; 64.4] versus 46 [35.6; 57.8] points, respectively, p<0.001), and satisfaction with treatment (75.1 [66.3; 88.8] versus 64 [48.8; 76.3] points, respectively, p<0.001). In the group of patients receiving Mildronate, a statistically significant decrease in the proportion of patients with of functional class (FC) IV (from 0.6% to 0%), FC III (from 15.9% to 2.1%) and FC II (from 51.1% to 40.2%) was observed compared to the control group (FC III — from 13.2% to 8.1% and FC II — from 50% to 45.3%) (p<0.001 between groups). In the group of patients taking Mildronate, a statistically significantly greater decrease in the total score on the subjective asthenia assessment scale (MFI-20) was observed compared to the control group (46.3 [38; 55] versus 63.3 [56; 71], p<0.001 between groups. Conclusion. The addition of Mildronate to combination therapy for the treatment of cardiovascular diseases for 42 days in obese patients with coronary heart disease and CHF is associated with a decrease in the severity of asthenia, an increase in satisfaction with treatment, a decrease in the frequency of attacks, and an improvement in the functional class of angina.

  • Open Access

    Statin-Induced Myopathy

    by D. A. Sychev, T. M. Ostroumova, O. D. Ostroumova, A. I. Kochetkov, S. V. Batyukina, E. V. Mironova

    Scientific relevance. Being the main class of medicinal products for dyslipidaemia treatment, statins are widely used in clinical practice in various patient populations. However, statins can cause statin-associated muscle symptoms (SAMS), which are the most frequent and, in some cases, even life-threatening adverse reactions associated with these medicinal products.Aim.The study aimed to perform a systematic review of the epidemiology, classification, and physiological pathogenesis of SAMS, risk factors for this complication, and clinical guidelines for primary care physicians regarding the identification and treatment of patients with SAMS.Discussion.SAMS is an umbrella term that covers various forms of myopathies associated with satin therapy. According to the published literature, the prevalence of SAMS varies considerably and may depend on the study design, inclusion criteria, and the medicinal product used. SAMS has multiple putative pathogenic pathways that include genetically determined processes, abnormalities in mitochondrial function, defects in intracellular signalling and metabolic pathways, and immune-mediated reactions. The main known risk factors for developing SAMS include high-dose statins, drug–drug interactions, genetic polymorphisms, female sex, older age, Asian race, history of kidney, liver, and muscle disease, and strenuous physical activity. Given the lack of universally recognised algorithms for diagnosing SAMS, clinicians should consider the clinical presentation and the temporal relationship between statin therapy and symptoms. Other factors to consider include changes in muscle-specific enzyme levels and, in some cases, the results of blood tests for antibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase.Conclusions.To ensure the safety of statin therapy, it is essential to raise clinicians’ awareness of the risk factors for SAMS, indicative clinical and laboratory findings, and the need for dynamic patient monitoring, including the involvement of clinical pharmacologists.


  • Open Access

    Psychological stress and cardiovascular diseases: clinical case

    by E. Yu. Ebzeeva, O. D. Ostroumova, E. V. Mironova, N. M. Doldo

    In the modern world, stress occupies a leading place among significant problems for humanity, being an etiological factor of about 80% of diseases. Social, physical and psychological factors can act as stressors that influence and determine the non-specific response of the body. In most cases, the nonspecific stress-induced reaction of the body is manifested by the picture of psychovegetative syndrome, an important component of which is the activation of the sympathetic nervous system. In a prolonged stress situation, psychovegetative syndrome can be a manifestation of stress-induced anxiety. Anxiety is detected in more than 25% of patients with a general somatic profile. Stress-induced reactions and anxiety can subsequently contribute to the development of psychogenic somatic pathology, including the cardiovascular pathology. Acute or chronic stress situation increases the risks of developing arterial hypertension, coronary heart disease, heart rhythm disorders. In the presence of background cardiac pathology, stress-induced reactions contribute to the deterioration of its course and reduce the effectiveness of treatment. The above indicates the need for a comprehensive assessment of the condition of patients with a general somatic profile. The active use in practical medicine of psychometric and psychodiagnostic scales for anxiety and depression is shown to assess the mental status of patients. When detecting stress-induced reactions or comorbid psychopathology, inclusion of psychotropic drugs, including antipsychotics (alimemazine), is indicated in the complex therapy. Timely administration of alimemazine in patients with a general somatic profile stops psychovegetative manifestations, has positive somatotropic effects due to the multimodal mechanism of action of the drug. In this clinical case, the use of alimemazine in a patient with hypertension, rhythm disorders and comorbid anxiety is presented.


  • Open Access

    Prospects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndrome

    by O. A. Polyakova, O. D. Ostroumova, E. V. Mironova, N. M. Doldo, A. I. Listratov, А. В. Филиппова

    The new coronavirus infection COVID-19 from the moment of the first message to the present has spread rapidly in more than two hundred countries around the world, posing a serious threat to the life and health of the population. Most patients who have recovered from COVID-19 continue to complain of shortness of breath, increased fatigue, chest pain, palpitations and other symptoms. Currently, the presence of symptoms 12 weeks after the acute phase of the new coronavirus infection COVID-19 is collectively referred to as post-covid syndrome. Studies have shown that this syndrome occurs frequently in recovered patients with COVID-19, regardless of their age and severity of the disease. This feature significantly distinguishes post-covid syndrome from other syndromes after an infection, and therefore the study of the mechanisms of its development, methods of diagnosis and treatment is an important public health problem. Particular attention is paid to patients with comorbidities, especially those with hypertension and cardiovascular diseases, since they have a more severe outcome after infection and higher case mortality rate. The current drug regimens for patients with post-covid syndrome and concomitant diseases are symptomatic. The most common manifestations of post-covid syndrome from the cardiovascular system are an increase in blood pressure and heart rate. In this regard, this review discusses the prospects for the use of a fixed combination of bisoprolol and amlodipine in the treatment of patients with post-covid syndrome, accompanied by an increase in blood pressure and heart rate.

  • Open Access

    Mechanisms and Consequences of Casein Kinase II regulation of the Epithelial Sodium Channel

    by Tarek Abd El‐Aziz, Antonio Soares, Elena Mironova, James Stockand

    Activity of the Epithelial Na + Channel, ENaC, in the distal nephron fine‐tunes renal sodium excretion. Appropriate renal sodium excretion is a key factor in the normal regulation of blood pressure. Consequently, dysregulation of ENaC causes hypertension. Casein Kinase II phosphorylates ENaC. The CKII phosphorylation site within ENaC resides within a canonical “anchor” ankyrin binding motif. The binding of Ank‐3 facilitates the proper membrane localization of ENaC increasing its activity. CKII‐dependent phosphorylation of ENaC is necessary and sufficient to increase channel activity and influence channel trafficking in a manner that increases activity. Herein, we tested the premise that phosphorylation of ENaC by CKII within “anchor” motifs is necessary and sufficient for ankyrin‐3 binding to the channel, which is required for normal channel locale and function, and the proper regulation of renal Na + excretion and blood pressure. This was addressed by combining total internal reflection fluorescence microscopy with fluorescence recovery after photo bleaching to follow movement of ENaC toward the plasma membrane in living cells and electrophysiology of ENaC activity in split‐open collecting ducts from principal cell‐specific CKII and Ank3 knockout mice. We also used whole animal physiological studies of sodium excretion in knockout mice to understand the physiological consequences of CKII and Ank3 regulation of ENaC. In addition, scanning mutagenesis was used to identify key residues in the overlapping CKII and Ank3 sites in ENaC. Findings showed that disrupting CKII signaling and abrogation of the CKII phosphorylation and Ank3 binding site within ENaC decreases channel trafficking toward the plasma membrane and activity, and promotes improper sodium excretion. These results showed that the CKII phosphorylation of ENaC functions as a “switch” that favors Ank‐3 binding to increase channel activity.

  • Open Access

    10 years of ARISTOTLE trial: results and lessons

    by Moscow Russian Medical Academy Of Continuous Professional Education, Olga D. Ostroumova, Vasiliy N. Butorov, Elena V. Mironova, Nikolai M. Doldo

    In 2021, the world cardiology community celebrates the anniversary of one of the greatest research in clinical medicine – the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study. The study showed that in patients with atrial fibrillation, the use of apixaban was more effective than the use of warfarin in the prevention of stroke or systemic embolism, was accompanied by a lower frequency of bleeding and was associated with lower mortality from all causes. To date, 77 subanalyses of this ambitious study have been published, a brief overview of which is given in the article. As shown by the post-hoc analysis of the ARISTOTLE study, apixaban was equally effective and safe both in patients without comorbidities and in polymorbid patients. The efficacy and safety of apixaban has been demonstrated in atrial fibrillation and in the presence of comorbidities, including diabetes mellitus, chronic kidney disease, obesity, and coronary heart disease. A number of subanalyses of the ARISTOTLE study are devoted to the prognostic assessment of biomarkers such as cardiac troponins, growth differentiation factor-15, pro-B-type N-terminal natriuretic peptide, D-dimer, asymmetric and symmetric dimethylarginine, interleukin-6, C-reactive protein. Based on the study of biomarkers, new, more informative scales for assessing the risk of stroke, death and bleeding were created: the ABC-stroke scale, the ABC-lethal outcome scale and the ABC-bleeding scale. The data of the corresponding sub-analyzes confirmed the greater efficacy and/or safety of apixaban treatment compared with warfarin, regardless of the level of various biomarkers in blood plasma and the degree of risk of stroke, death and bleeding, assessed using both traditional and new scales.


  • Myocardial injury in coronavirus infection combined with lung, skin and kidney lesions: clinical case and literature review

    by Russian Medical Academy Of Continuing Professional Education, Jebzeeva E.YU, E.V. Mironova, Russian Railways Medicine, I.F. Krotkova, V.A. De, O.D. Ostroumova

    Th e most common clinical manifestation of new coronavirus infection is bilateral pneumonia. At the same time, COVID-19 has a wide range of cardiovascular complications, with the development of acute heart failure, arrhythmias, acute coronary syndrome, and myocarditis. Myocardial injury is relatively common in COVID-19, accounting 7-23 % of cases. Th e presented clinical case describes a 56-year-old patient with a confi rmed coronavirus infection. Th e peculiarity of this clinical case is that it is the first report on COVID-19 with systemic manifestations: lungs, heart, kidneys and skin lesions. It should be noted that despite viral pneumonia typical for COVID-19, clinical picture and severity of the patient’s condition were determined by the developed myocardial injury. Th e presented clinical case is specifi c due to skin lesions